Facioscapulohumeral muscular dystrophy (FSHD) is a rare and disabling condition with an 4 9 cycles of pre-amplification, reactions were diluted 5-fold in nuclease-free water and qPCR was 1 5 8 performed using taqman multiplex master mix (Thermofisher cat#4461882). 1 5 9
To measure DUX4 target gene expression in a 96-well plate format, cells were lysed into 25 μ L 1 6 0 Realtime Ready lysis buffer (Roche, #07248431001) containing 1% RNAse inhibitor (Roche, 1 6 1 #03335399001) and 1% DNAse I (ThermoFisher, #AM2222) for 10 min while shaking on a 1 6 2 vibration platform shaker (Titramax 1000) at 1200 rpm. After homogenization, lysates were 1 6 3 frozen at -80 o C for at least 30 min and thawed on ice. Lysates were diluted to 100 μ L using 1 6 4
RNase-free water. 1 μ L of this reaction was used for reverse transcription and preamplification 1 6 5 of cDNA in a 5 μ L one-step reaction using the RT enzyme from Taqman RNA-to-Ct 1 6 6 (ThermoFisher, #4392938) and the Taqman Preamp Master Mix (ThermoFisher, #4391128) 1 6 7 according to manufacturer's specifications. This preamplification reaction was diluted 1:4 using 1 6 8 nuclease-free water, 1μL of this reaction was used as input for a 5 μ L qPCR reaction using the 1 6 9
Taqman Multiplex Master Mix (ThermoFisher, #4484262). Amplification was detected in a 1 7 0 Quantstudio 7 Flex instrument from ThermoFisher. The following Taqman probes were 1 7 1 purchased from ThermoFisher; MBD3L2 Taqman Assay (ThermoFisher, Hs00544743_m1, 1 7 2 FAM-MGB). ZSCAN4 Taqman Assay (ThermoFisher, Hs00537549_m1, FAM-MGB). LEUTX 1 7 3
Taqman Assay (Thermo Fisher, Hs01028718_m1, FAM-MGB). TRIM43 Taqman Assay 1 7 4 (ThermoFisher, Hs00299174_m1, FAM-MGB). KHDC1L Taqman Assay (ThermoFisher, 1 7 5
Hs01024323_g1, FAM-MGB). POLR2A Taqman Assay (ThermoFisher, Hs00172187_m1, VIC-1 7 6 MGB). 1 7 7 Detection of HSP27 by Electrochemiluminescence 1 7 8
Total and phosphorylated HSP27 was measured using a commercial MesoScale Discovery 1 7 9 assay, Phospho (Ser82)/Total HSP27 Whole Cell Lysate Kit (MesoScale Discovery, # 1 8 0 K15144D). Myotubes were grown in 96-well plates using conditions described above and were 1 8 1 lysed using 25 μ L of 1X MSD lysis buffer with protease and phosphatase inhibitors. The lysates 1 8 2 were incubated at room temp for 10 minutes with shaking at 1200 rpm using Titramax 1000. 1 8 3
Lysates were stored at -80 o C until all timepoints were collected. Lysates were then thawed on 1 8 4 ice and 2 μ L were used to perform a BCA protein assay (ThermoFisher, # 23225). 10 μ L of 1 8 5 lysate were diluted 1:1 in 1X MSD lysis buffer and added to the 96-well Mesoscale assay plate. 1 8 6
Manufacturer instructions were followed, and data was obtained using a MesoScale Discovery 1 8 7 SECTOR S 600 instrument. 1 8 8 imaging. Images were collected using the CellInsight CX7 (ThermoFisher). Images were 2 1 9 quantified using HCS Studio Software. Differentiation was quantified by counting the percentage 2 2 0 of nuclei in cells expressing MHC from the total of the well. SLC34A2 and active Caspase-3 2 2 1 signal was quantified by colocalization of cytoplasmic cleaved Caspase-3 within MHC 2 2 2 expressing cells. 2 2 3
Knockdown of MAPK12 and MAPK14 in FSHD myotubes 2 2 4
Exponentially dividing immortalized C6 FSHD myoblasts were harvested and counted. 50000 2 2 5 myoblasts were electroporated using a 10 μ L tip in a Neon electroporation system 2 2 6 (ThermoFisher). Conditions used were determined to preserve viability and achieved maximal 2 2 7 electroporation (Pulse V=1100V, pulse width=40 and pulse #=1). After electroporation, cells 2 2 8 were plated in growth media and media was changed for differentiation 24h after. 3 days after 2 2 9 differentiation, cells were harvested and analyzed for KD and effects in MBD3L2 using the RT-2 3 0 qPCR assay described before. siRNAs used were obtained from ThermoFisher (4390843, 2 3 1 4390846, s3585, s3586, s12467, s12468).
3 2
Gene expression analysis by RNA-seq 2 3 3 RNA from myotubes grown in 6-well plates in conditions described above was isolated using the 2 3 4 RNeasy Micro Kit from Qiagen (#74004). Quality of RNA was assessed by using a Bioanalyzer 2 3 5 2100 and samples were submitted for library preparation and deep sequencing to the Molecular 2 3 6 biology core facility at the Dana Farber Cancer Institute. After sequencing, raw reads of fastq 2 3 7 files from all samples were mapped to hg38 genome assemblies using ArrayStudio aligner. Raw 2 3 8 read count and FPKM were calculated for all the genes, and DESeq2 was applied to calculate 2 3 9 differentially expressed genes using general linear model (GLM To model FSHD in vitro, we differentiated FSHD1 patient-derived immortalized myoblasts into 2 4 6 skeletal muscle myotubes. We allowed myoblasts to reach >70% confluency and added 2 4 7 differentiation medium lacking growth factors ( Figure 1A ) (Brewer et al., 2008; Krom et al., 2012;  2 4 8 Thorley et al., 2016) . After one day of differentiation, we detected DUX4 expression by RT-2 4 9 qPCR and its expression increased throughout the course of myogenic fusion and formation of 2 5 0 post-mitotic, multinucleated FSHD myotubes ( Figure 1B ). Because of the stochastic and low 2 5 1 expression levels of DUX4 in FSHD cells, we measured DUX4-regulated genes as an amplified 2 5 2 readout of the expression and activity of DUX4. These include ZSCAN4, MBD3L2, TRIM43, 2 5 3 LEUTX and KHDC1L which are among the most commonly described DUX4 targets (Geng et 2 5 4 al., 2011; Tasca et al., 2012; Yao et al., 2014; Jagannathan et al., 2016; Chen et al., 2016;  2 5 5 Whiddon et al., 2017; Wang et al., 2018) . These genes were downregulated after DUX4 2 5 6 antisense oligonucleotide treatment of FSHD myotubes and were nearly undetectable or 2 5 7 completely absent in FSHD myoblasts or wild-type myotubes ( Figure 1C ). We concluded that 2 5 8 these transcripts were solely dependent on DUX4 expression in differentiating myotubes.
5 9
Although a number of DUX4-dependent transcripts have been previously described, we 2 6 0 selected an assay to specifically detect MBD3L2 for high-throughput screening because it 2 6 1 displayed the best signal window of differential expression in our in vitro system comparing 2 6 2 FSHD to healthy wildtype myotubes ( Figure 1D ). With this assay, we identified several small 2 6 3 molecules that reduced MBD3L2 expression after 5 days of differentiation and treatment and 2 6 4 showed good reproducibility across replicates ( Figure 1E ). Validating our results, we found 2 6 5 several molecules identified previously to reduce DUX4 expression, including BET inhibitors and 2 6 6 β -adrenergic agonists exemplified in Figure S1 (Campbell et al., 2017; Cruz et al., 2018) . 2 6 7
However, when treating differentiating FSHD myotubes in our assay, we observed a reduction 2 6 8 in fusion as indicated by visual inspection and by the reduction of MYOG expression with BET 2 6 9 inhibitors. Importantly, we identified multiple scaffolds that inhibit p38 α and β and strongly 2 7 0 inhibit the expression of MBD3L2 without affecting differentiation. 2 7 1 p38α signaling participates in the activation of DUX4 expression in FSHD myotubes 2 7 2 Potent and selective inhibitors of p38α/β have been previously explored in multiple clinical 2 7 3 studies for indications associated with the role of p38α in the regulation of the expression of 2 7 4 inflammatory cytokines and cancer (Coulthard et al., 2009) . We tested several p38α/β inhibitors 2 7 5 of different chemical scaffolds in our assays which showed significant inhibition of MBD3L2 2 7 6 expression ( Figure 2A ). Importantly, half maximal inhibitory concentrations (IC 50 ) obtained for 2 7 7 MBD3L2 reduction were comparable to reported values by other groups in unrelated cell-based 2 7 8 assays that measured p38 α /β inhibition, suggesting the specificity for the assigned 2 7 9 target (Underwood et al., 2000; Campbell et al., 2014; Fehr et al., 2015) . P38α and β kinases 2 8 0 phosphorylate a myriad of substrates, including downstream kinases like MAPKAPK2 (also 2 8 1 known as MK2) which phosphorylates effector molecules such as heat shock protein 27 2 8 2 (HSP27), as well as a variety of transcription factors including myogenic transcription factors like 2 8 3 MEF2C (Simone et al., 2004; Knight et al., 2012; Segalés, Perdiguero, et al., 2016) . To 2 8 4 determine p38α/β signaling activity in differentiating myoblasts, we measured the levels of 2 8 5 phosphorylation of HSP27. As reported previously, we observed increased p38 signaling rapidly 2 8 6 upon addition of differentiation media ( Figure S2 ) (Perdiguero et al., 2007) . We observed P38α/β 2 8 7 inhibitors reduced phosphorylated HSP27 levels with similar IC 50 values to that of MBD3L2 2 8 8 ( Figure 2B ). To further validate our findings, we electroporated FSHD myoblasts with siRNAs 2 8 9 against p38 α and γ , the most abundant p38 MAPKs in skeletal muscle. After 3 days of 2 9 0 differentiation, transient knockdown of p38α showed robust inhibition of expression of MBD3L2 2 9 1 in FSHD myotubes ( Figure 2C ) and no significant effects in fusion were observed ( Figure S3 ).
9 2
We observed that close to 50% reduction of MAPK14 (p38α) mRNA was sufficient to inhibit MBD3L2 expression without impacting myogenesis and this level of reduction may account for 2 9 4 the differences on myogenesis observed between this study and those previously reported 2 9 5 using p38 mouse knockout myoblasts (Perdiguero et al., 2007) . 2 9 6
Our results suggest the p38α pathway is an activator of DUX4 expression in FSHD muscle cells 2 9 7 undergoing differentiation. To further understand the reduction in DUX4 expression, we 2 9 8 measured the expression of DUX4 transcript and protein upon inhibition of p38 α and β . To 2 9 9 measure protein, we developed a highly sensitive assay based on the electrochemiluminescent 3 0 0 detection of DUX4 on the Mesoscale Diagnostics (MSD) platform using two previously 3 0 1 generated antibodies ( Figure S4 ). We observed that p38α/β inhibition resulted in a highly 3 0 2 correlated reduction of DUX4 transcript and protein ( Figure 2D ). We concluded this led to the 3 0 3 reduction in the expression of DUX4 target gene, MBD3L2. et al., 2007; Wissing et al., 2014; Segalés, Perdiguero, et al., 2016; Segalés, Islam, 3 0 9 et al., 2016) . We developed a quantitative assay to measure cell fusion and myotube formation 3 1 0 to assess skeletal muscle differentiation in vitro. In this assay, we stained immortalized FSHD 3 1 1 myotubes cells using antibodies against Myosin Heavy Chains (MHC) and quantified the 3 1 2 number of nuclei detected inside MHC-stained region. This provided a way to quantitate the 3 1 3 number of cells that successfully underwent the process of in vitro myogenesis. P38α/β 3 1 4 inhibition by LY2228820 and GW856553X (losmapimod) did not impact differentiation of 3 1 5 myoblasts into skeletal muscle myotubes. Treated cells fused properly at all tested drug 3 1 6 concentrations to levels comparable to the DMSO control ( Figure 3A ). 3 1
We also further assessed gene expression changes in FSHD myotubes upon p38α/β inhibition. 3 1 8
We performed RNA-seq analysis of FSHD and WT myotubes after four days of treatment with 3 1 9 vehicle or p38α/β inhibitors. Inhibition of the p38 signaling pathway during differentiation did not 3 2 0 induce significant transcriptome changes, and resulted in less than 100 differentially expressed 3 2 1 genes (abs(FC)>4; FDR<0.001). About 80% of these differentially expressed genes were known 3 2 2 DUX4-regulated transcripts and were all downregulated after p38 α and β inhibition ( Figure 3B ). 3 2 3
This set of DUX4-regulated genes overlapped significantly with genes upregulated in FSHD 3 2 4 patient muscle biopsies (Wang et al., 2018) . Moreover, key driver genes of myogenic programs 3 2 5 such as MYOG, MEF and PAX genes and markers of differentiation such as myosin subunits 3 2 6 and sarcomere proteins were not affected by p38 inhibition ( Figure 3C ). 3 2 7
Inhibition of DUX4 expression results in the reduction of cell death in FSHD myotubes 3 2 8 DUX4 activation and downstream DUX4-regulated target gene expression in muscle cells is 3 2 9 toxic, leading to oxidative stress, changes in sarcomere organization, and apoptosis, 3 3 0 culminating in reduced contractility, and muscle tissue replacement by fat (Block et al., 2013;  3 3 1 Bosnakovski et al., 2014; Tawil et al., 2014; Rickard et al., 2015; Homma et al., 2015;  Choi et 3 3 2 al., 2016). In particular, apoptotic cells have been detected in skeletal muscle of FSHD patients 3 3 3 supporting the hypothesis that programmed cell death is caused by aberrant DUX4 expression 3 3 4 and contributes to FSHD pathology (Sandri et al., 2001; Statland et al., 2015) . To test this 3 3 5 hypothesis in vitro, we evaluated the effect of p38α/β inhibition on apoptosis in FSHD myotubes. 3 3 6
We used an antibody recognizing caspase-3 cleavage products by immunofluorescence to 3 3 7 quantify changes in the activation of programmed cell death. Cleavage of caspase-3 is a major 3 3 8 step in the execution of the apoptosis signaling pathway, leading to the final proteolytic steps 3 3 9 that result in cell death (Fuentes-Prior and Salvesen, 2004; Dix et al., 2008; Mahrus et al., 3 4 0 2008). We detected activated caspase-3 in FSHD but not in wild-type myotubes and observed a 3 4 1 stochastic pattern of expression of DUX4 in FSHD as previously reported ( Figure 4A ) (Snider et al., 2010; Jones et al., 2012; van den Heuvel et al., 2018) . Levels of cleaved caspase-3 were 3 4 3 reduced in a concentration-dependent manner with an IC 50 similar to what we observed for 3 4 4 inhibition of the p38 pathway and DUX4 expression ( Figure 4B ). Moreover, we measured 3 4 5 SLC34A2, a DUX4 target gene product using a similar immunofluorescence assay ( Figure 3B ). 3 4 6
This protein was expressed in a similar stochastic pattern observed for active caspase-3 and its 3 4 7 expression was also reduced by p38α/β inhibition ( Figure 4B FSHD is caused by the loss of repression at the D4Z4 locus leading to DUX4 expression in 3 5 2 skeletal muscle due to the contraction in the D4Z4 repeat arrays in chromosome 4 or by 3 5 3 mutations in SMCHD1 and other modifiers such as DNMT3B. Primary FSHD myotubes were 3 5 4 used to study the in vitro efficacy of p38α/β inhibitors across different genotypes. We tested 3 5 5 eight FSHD1 primary myoblasts with 2-7 D4Z4 repeat units and three FSHD2 cell lines with 3 5 6 characterized SMCHD1 mutations. Upon differentiation, the primary cells tested expressed a 3 5 7 wide range of MBD3L2 levels ( Figure 5A , number of D4Z4 repeat units or SMCHD1 mutation 3 5 8 indicated in parenthesis), comparable to what we and others have observed in other FSHD 3 5 9 myotubes (Jones et al., 2012). However, we observed significant inhibition of the DUX4 3 6 0 program expression following treatment with multiple p38α/β inhibitors in all primary myotubes 3 6 1 tested from FSHD1 and FSHD2 patients ( Figure 5B ). Furthermore, this reduction in the DUX4 3 6 2 program resulted in concomitant reduction of cleaved caspase-3 ( Figure 5C ) without any 3 6 3 measurable effects on myotube differentiation ( Figure 5D ). Our results suggest that the p38α/β 3 6 4 pathway critically regulates the activation of DUX4 independently of the mutation driving its 3 6 5 expression in FSHD muscle cells. 3 6 6 DISCUSSION 3 6 7
Recent studies have advanced our understanding of the mechanisms that normally lead to the 3 6 8 establishment and maintenance of repressive chromatin at the D4Z4 repeats. Similar to other 3 6 9
repetitive elements in somatic cells, chromatin at this locus is decorated by DNA methylation 3 7 0 and other histone modifications associated with gene silencing, such as H3K27me3 and 3 7 1 H3K9me3 (van Overveld et al., 2003; Zeng et al., 2009; Cabianca et al., 2011; Huichalaf et al., In this study, by modelling FSHD in vitro and screening a library of probe molecules, we 3 8 5 identified p38α as a novel activator of DUX4 expression in patient-derived FSHD cells. This 3 8 6 signaling kinase directly phosphorylates transcription factors involved in myogenesis and may 3 8 7 signal directly to activate DUX4 expression in differentiating myoblasts. Using highly selective 3 8 8 and potent small molecules extensively characterized previously, we have studied the 3 8 9 pharmacological relationships between the inhibition of this signaling pathway and the inhibition 3 9 0 of the expression of DUX4, its downstream gene program expression and its consequences in muscle cells from FSHD patients. These relationships are maintained across multiple FSHD 3 9 2 genotypes, including FSHD1 and FSHD2, indicating that this mechanism acts independent of 3 9 3 the genetic lesion present in these patients. Our studies show a specific effect of p38 α and β 3 9 4 inhibition in downregulation of the DUX4 program and normalization of gene expression 3 9 5 compared to cells from healthy donors. Notably, no effects in differentiation were detected at the 3 9 6 tested concentrations of p38 inhibitor. 3 9 7
Other recent efforts to identify targets for the treatment of FSHD have reported similar studies in 3 9 8 which the investigators followed the expression of MBD3L2 as a readout for DUX4 expression 3 9 9 or by using a reporter driven by the activity of DUX4 in immortalized FSHD myotubes in vitro 4 0 0 (Campbell et al., 2017; Cruz et al., 2018) . Our results have reproduced their identification of β -4 0 1 adrenergic agonists and BET inhibitors as inhibitors of DUX4 expression. However, these 4 0 2 molecules also caused downregulation of the transcription factor MYOG expression or affected 4 0 3 myoblasts fusion at concentrations similar to the half maximal inhibitory concentration for DUX4 4 0 4 expression inhibition in our model ( Figure S1B , lack of fusion indicated by arrow). Recently, an 4 0 5 independent study reported that p38α/β inhibitors inhibit expression of DUX4 further validating 4 0 6 findings reported here. Importantly in this study, they showed that p38α/β inhibitors are 4 0 7 efficacious in downregulating expression of DUX4 in a xenograft mouse model of FSHD. 4 0 8
In humans, previous clinical studies evaluating p38α/β inhibitors in non-FSHD indications under 4 0 9 an anti-inflammatory therapeutic hypothesis were tested extensively and shown to be safe and 4 1 0 tolerable. However, they never met efficacy endpoints in diseases such as rheumatoid arthritis, 4 1 1 chronic obstructive pulmonary disease and acute coronary syndrome (Hill et al., 2008;  4 1 2 Damjanov et al., 2009; Hammaker and Firestein, 2010; Barbour et al., 2013; MacNee et al., 4 1 3 2013; Norman, 2015; Patnaik et al., 2016) . Here, we present further evidence from in vitro 4 1 4 studies that support the therapeutic hypothesis of treatment of FSHD at its root cause, 4 1 5 prevention or reduction of aberrant expression of DUX4, via inhibition of p38 α /β. 4 1 6 ACKNOWLEDGEMENTS 4 1 7
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